Biotheus Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO30%
Delay Index: of 10 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Biotheus Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PM8002 NCT05844150 |
P2 | Active, not recruiting | SCLC | 50 | 2024-05-10 (-13 mo) |
| PM8002 NCT05756972 |
P2 | Active, not recruiting | NSCLC | 64 | 2024-09-13 (-6 mo) |
| PM8002 NCT05879068 |
P2 | Active, not recruiting | SCLC | 99 | 2025-04-30 (+12 mo) |
| PM8002 NCT05918445 |
P1/2 | Recruiting | Malignant Neoplasm | 380 | 2025-11-30 (+24 mo) |
| PM8002 NCT06584071 |
P1/2 | Not yet recruiting | HCC; Liver Cancer | 140 | 2026-10 |
| PM8002 NCT05918133 |
P1/2 | Active, not recruiting | TNBC | 42 | 2026-10-30 |
| PM8002 NCT05879055 |
P2 | Active, not recruiting | Neuroendocrine Neoplasm | 31 | 2027-01-01 |
| PM8002 NCT06616532 |
P3 | Active, not recruiting | SCLC | 404 | 2027-05 (+3 mo) |
| PM8002 NCT07133750 |
P2 | Recruiting | CRC (Colorectal Cancer) | 100 | 2027-05 (+9 mo) |
| PM8002 NCT06419621 |
P3 | Active, not recruiting | Triple Negative Breast Cancer(TNBC) | 392 | 2027-07 |